Samuel Murray
www.linkedin.com
0000-0003-0074-6462
Memorial Sloan Kettering Cancer Center
4 papers found
Refreshing results…
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
The role of IL-6 in neurodevelopment after prenatal stress
Missing publications? Search for publications with a matching author name.